Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.

Authors

Michael R Bristow
Kavita Sharma
Susan F Assmann
Stuart Linas
Bernard J Gersh
Christine Grady
Madeline Murguia Rice, George Washington University
Steven Singh
Robin Boineau
Sonja M McKinlay
Barry H Greenberg

Document Type

Journal Article

Publication Date

4-1-2017

Journal

European Journal of Heart Failure : Journal of the Working Group on Heart Failure of the European Society of Cardiology

Volume

19

Issue

4

DOI

10.1002/ejhf.686

Keywords

Clinical Trials Data Monitoring Committees; Clinical Trials as Topic; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Patient Safety; Renal Insufficiency; Spironolactone

APA Citation

Bristow, M., Sharma, K., Assmann, S., Linas, S., Gersh, B., Grady, C., Rice, M., Singh, S., Boineau, R., McKinlay, S., & Greenberg, B. (2017). Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.. European Journal of Heart Failure : Journal of the Working Group on Heart Failure of the European Society of Cardiology, 19 (4). http://dx.doi.org/10.1002/ejhf.686

Peer Reviewed

1